To investigate the distinctive features of PGE2 depletion or IFN-I response reinstatement in patients with cancer, we established a signature of the top upregulated genes in immune cells after Ptgs1/2 KO (TME-COX signature, n = 26) and the top upregulated genes after IRF3/7 overexpression (TME-IRF3/7 signature, n = 40; Supplementary Table 4). The gene discussed is IRF3; the disease is cancer.